April 5, 2022
Paxlovid (PF-07321332/ritonavir) does not have a Marketing Authorization. It has been granted an Emergency Use Authorization (EUA) by the Tunisia Ministry of Health for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.